165 related articles for article (PubMed ID: 36602798)
1. Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.
Brazel D; Kumar P; Doan H; Pan T; Shen W; Gao L; Moyers JT
JAMA Netw Open; 2023 Jan; 6(1):e2249674. PubMed ID: 36602798
[TBL] [Abstract][Full Text] [Related]
2. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
3. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.
Cohen PR; Tomson BN; Elkin SK; Marchlik E; Carter JL; Kurzrock R
Oncotarget; 2016 Apr; 7(17):23454-67. PubMed ID: 26981779
[TBL] [Abstract][Full Text] [Related]
4. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
5. Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.
Harms KL; Lazo de la Vega L; Hovelson DH; Rahrig S; Cani AK; Liu CJ; Fullen DR; Wang M; Andea AA; Bichakjian CK; Johnson TM; Tomlins SA; Harms PW
JAMA Dermatol; 2017 Jun; 153(6):505-512. PubMed ID: 28403382
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
7. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
8. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
9. Activation of PI3K signaling in Merkel cell carcinoma.
Nardi V; Song Y; Santamaria-Barria JA; Cosper AK; Lam Q; Faber AC; Boland GM; Yeap BY; Bergethon K; Scialabba VL; Tsao H; Settleman J; Ryan DP; Borger DR; Bhan AK; Hoang MP; Iafrate AJ; Cusack JC; Engelman JA; Dias-Santagata D
Clin Cancer Res; 2012 Mar; 18(5):1227-36. PubMed ID: 22261808
[TBL] [Abstract][Full Text] [Related]
10. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
12. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
13. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy.
Kang H; Pettinga D; Schubert AD; Ladenson PW; Ball DW; Chung JH; Schrock AB; Madison R; Frampton GM; Stephens PJ; Ross JS; Miller VA; Ali SM
Oncologist; 2019 Jun; 24(6):791-797. PubMed ID: 30373905
[TBL] [Abstract][Full Text] [Related]
14. UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
Wong SQ; Waldeck K; Vergara IA; Schröder J; Madore J; Wilmott JS; Colebatch AJ; De Paoli-Iseppi R; Li J; Lupat R; Semple T; Arnau GM; Fellowes A; Leonard JH; Hruby G; Mann GJ; Thompson JF; Cullinane C; Johnston M; Shackleton M; Sandhu S; Bowtell DD; Johnstone RW; Fox SB; McArthur GA; Papenfuss AT; Scolyer RA; Gill AJ; Hicks RJ; Tothill RW
Cancer Res; 2015 Dec; 75(24):5228-34. PubMed ID: 26627015
[TBL] [Abstract][Full Text] [Related]
15. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
[TBL] [Abstract][Full Text] [Related]
17. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
18. Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors.
Harms PW; Verhaegen ME; Hu K; Hrycaj SM; Chan MP; Liu CJ; Grachtchouk M; Patel RM; Udager AM; Dlugosz AA
Mod Pathol; 2022 Apr; 35(4):506-514. PubMed ID: 34593967
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
Attalla K; DiNatale RG; Rappold PM; Fong CJ; Sanchez-Vega F; Silagy AW; Weng S; Coleman J; Lee CH; Carlo MI; Durack JC; Solomon SB; Reuter VE; Russo P; Chan TA; Motzer RJ; Schultz ND; Reznik E; Voss MH; Hakimi AA
Clin Cancer Res; 2021 Oct; 27(20):5595-5606. PubMed ID: 34261695
[TBL] [Abstract][Full Text] [Related]
20. Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal.
DeCoste RC; Carter MD; Pasternak S; Fleming KE; Gaston D; Legge A; Ly TY; Walsh NM
Hum Pathol; 2021 Nov; 117():31-41. PubMed ID: 34391748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
